A new study found that compared to those with BRCA2 mutations outside exon 11, those with exon 11 mutations had a lower breast cancer risk, higher risk for ER-negative breast cancer, and later age at diagnosis. These findings suggest that taking mutation type and location into account in cancer risk models may improve the ability …
Date Range: 2025 (2) Fall
Permanent link to this article: https://inheritedcancer.net/nlf20255/
ICARE Newsletter Fall 2025
National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment Guideline Updates
ICARE Newsletter Fall 2025
National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment Guideline Updates
Select updates outlined below. Check out the full guidelines by creating a FREE account at https://www.nccn.org/guidelines/category_2 Colorectal, Endometrial, & Gastric Cancer V1.2025 – Released June 13th, 2025 Breast, Ovarian, Pancreatic, & Prostate Cancer V1.2026 – Released July 10th, 2025
Permanent link to this article: https://inheritedcancer.net/nlf20251/
ICARE Newsletter Fall 2025
BRCA1/2 Carriers: High Risk of Breast Implant-Associated Lymphoma
ICARE Newsletter Fall 2025
BRCA1/2 Carriers: High Risk of Breast Implant-Associated Lymphoma
In a new study of female BRCA1/2 carriers who had breast cancer, there was a 16-fold higher risk of anaplastic large-cell lymphoma associated with breast implants. This occurred in BRCA1/2 carriers who received textured breast implants as part of breast reconstruction. This is important information for BRCA1/2 carriers to know about to guide breast reconstruction …
Permanent link to this article: https://inheritedcancer.net/nlf20254/
ICARE Newsletter Fall 2025
BRIP1: Third Most Common Gene for Inherited Ovarian Cancer
ICARE Newsletter Fall 2025
BRIP1: Third Most Common Gene for Inherited Ovarian Cancer
In a new study of unselected women with ovarian cancer, BRIP1 was the third most common gene for inherited ovarian cancer at a frequency of 1.1%, following BRCA1/2 which were found in 14.8%. Other inherited ovarian cancer genes included PALB2 (0.8%), RAD51C (0.4%), and RAD51D (0.4%). Beyond BRCA1/2 testing, additional testing through inherited cancer multi-gene …
Permanent link to this article: https://inheritedcancer.net/nlf20256/
ICARE Newsletter Fall 2025
BRCA1/2 Carriers with Breast Cancer: Removal of Ovaries and Fallopian Tubes Lowers Risk of Death
ICARE Newsletter Fall 2025
BRCA1/2 Carriers with Breast Cancer: Removal of Ovaries and Fallopian Tubes Lowers Risk of Death
A new study among BRCA1/2 carriers with breast cancer showed that the overall risk of death was 48% lower for those that removed their ovaries and fallopian tubes. Specifically, these women had lower risks of all-cause mortality, breast cancer-specific mortality, and second non-breast cancer development. Removing the ovaries leads to menopause which has other health …
Permanent link to this article: https://inheritedcancer.net/nlf20252/
ICARE Newsletter Fall 2025
ATM, CHEK2, & PALB2 Carriers: Are There Differences in Cancer-Associated Mortality?
ICARE Newsletter Fall 2025
ATM, CHEK2, & PALB2 Carriers: Are There Differences in Cancer-Associated Mortality?
A new study of ATM, CHEK2, and PALB2 carriers compared to non-carriers showed similar mortality from breast cancer, pancreatic cancer, and colorectal cancer. Other findings among BRCA1/2 carriers and Lynch Syndrome patients showed: 1) BRCA1/2 carriers had lower mortality from triple-negative breast cancer; and 2) Lynch Syndrome patients had lower mortality from colorectal cancer. Ultimately, …
Permanent link to this article: https://inheritedcancer.net/nlf20257/
ICARE Newsletter Fall 2025
Ask the Expert
ICARE Newsletter Fall 2025
Ask the Expert
The question was addressed by Brian Shirts, MD, PhD, President of ConnectMyVariant and Service Medical Director of the Molecular Genetics Laboratories at Vanderbilt University Medical Center. If you have a question you would like addressed, email ICARE@vumc.org for consideration in future newsletters. Q: Why do you think cascade testing has not happened as much as …
Permanent link to this article: https://inheritedcancer.net/nlf202511/
ICARE Newsletter Fall 2025
Ovarian Cancer: 1 in 4 Cases Could Have Been Prevented!
ICARE Newsletter Fall 2025
Ovarian Cancer: 1 in 4 Cases Could Have Been Prevented!
A new study of 1877 ovarian cancer patients showed almost 25% of patients had ‘missed opportunities’ for salpingectomy (removal of fallopian tubes) when they had another surgery or procedure before their ovarian cancer diagnosis. Additionally, 6% of patients had a close relative with ovarian cancer, and almost 20% had a mutation in an ovarian cancer …
Permanent link to this article: https://inheritedcancer.net/nlf20253/
ICARE Newsletter Fall 2025
Lynch Syndrome: Showing the Importance of Family Testing
ICARE Newsletter Fall 2025
Lynch Syndrome: Showing the Importance of Family Testing
Cascade testing refers to testing family members for a gene mutation after another family member is found to have a mutation. Once family members get cascade testing, they can also benefit from screening, cancer prevention, and early detection strategies. A study conducted a microsimulation model to look at the cost effectiveness of cascade testing of …
Permanent link to this article: https://inheritedcancer.net/nlf20258/
ICARE Newsletter Fall 2025
ICARE Community Spotlight: Kathy Baker
ICARE Newsletter Fall 2025
ICARE Community Spotlight: Kathy Baker
I was only 30 when my 32-year-old sister was diagnosed with breast cancer. A couple years later, when a mobile mammography bus showed up at my law school offering free mammograms, I decided it couldn’t hurt to be screened. When my mammogram was normal, I made plans to wait until age 50 for my next …
Permanent link to this article: https://inheritedcancer.net/nlf202512/
ICARE Newsletter Fall 2025
Inherited Prostate Cancer: PARP Inhibitors
ICARE Newsletter Fall 2025
Inherited Prostate Cancer: PARP Inhibitors
A new study combined the results of prior studies of PARP inhibitors in patients with metastatic castration-resistant prostate cancer and an inherited gene mutation through a meta-analysis. The results showed that PARP inhibitors provided the greatest benefit in BRCA1/2 carriers and there was a strong signal of benefit in PALB2 or CDK12 alterations. However, there …
Permanent link to this article: https://inheritedcancer.net/nlf202510/
ICARE Newsletter Fall 2025
Breast Cancer Treatment: BRCA1/2 Carriers
ICARE Newsletter Fall 2025
Breast Cancer Treatment: BRCA1/2 Carriers
A new randomized controlled trial among BRCA1/2 carriers comparing neoadjuvant chemotherapy with olaparib versus chemotherapy alone found: These findings suggest that adding olaparib may benefit survival for BRCA1/2 carriers, even if this is not apparent when looking at pathologic response. Abraham, et al. Nat Commun. 2025;16(1):4269. PMID: 40360463. Article available at: https://pubmed.ncbi.nlm.nih.gov/40360463/. Social media post …
Permanent link to this article: https://inheritedcancer.net/nlf20259/
ICARE Social Media Post August 2025
NCCN BOPP Guidelines (V1.2026): TP53
ICARE Social Media Post August 2025
NCCN BOPP Guidelines (V1.2026): TP53
The National Comprehensive Cancer Network (NCCN) recently released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate Cancer guidelines (Version 1.2026), which included updates to TP53 content. To learn more, check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_bopp.pdf
Permanent link to this article: https://inheritedcancer.net/post082125/
ICARE Social Media Post August 2025
New Gene Alert: RPS20
ICARE Social Media Post August 2025
New Gene Alert: RPS20
🚨 New Gene Alert! 🚨RPS20 has been identified as a colorectal cancer risk gene: Learn more at:https://pubmed.ncbi.nlm.nih.gov/39920491/Reference: Amiot et al. Fam Cancer. 2025;24(1):22. PMID: 39920491. https://www.gimopen.org/article/S2949-7744(25)00981-1/fulltextReference: Herrera-Mullar et al. Genetics in Medicine Open. 2025;3(2):2949-7744. DOI: 10.1016/j.gimo.2025.102942
Permanent link to this article: https://inheritedcancer.net/post081925/
ICARE Social Media Post August 2025
NCCN BOPP Guidelines (V1.2026): PTEN
ICARE Social Media Post August 2025
NCCN BOPP Guidelines (V1.2026): PTEN
The National Comprehensive Cancer Network (NCCN) recently released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate Cancer guidelines (Version 1.2026), which included updates to PTEN content. To learn more, check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_bopp.pdf
Permanent link to this article: https://inheritedcancer.net/post081425/
ICARE Social Media Post August 2025
Lynch Syndrome: Low Dose Aspirin Lowers Colorectal Cancer Risk
ICARE Social Media Post August 2025
Lynch Syndrome: Low Dose Aspirin Lowers Colorectal Cancer Risk
According to new results of the Colorectal Adenoma/Carcinoma Prevention Program 3 (CaPP3) study presented at the International Cancer Prevention Conference in London, low-dose aspirin (100 mg) lowered the risk of colorectal cancer in patients with Lynch syndrome. Additionally, the use of aspirin lowered the risk of all cancers associated with Lynch syndrome. Learn more by …
Permanent link to this article: https://inheritedcancer.net/post081225/
ICARE Social Media Post August 2025
NCCN CEG Guidelines (V1.2025): CDH1 Post
ICARE Social Media Post August 2025
NCCN CEG Guidelines (V1.2025): CDH1 Post
The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, Gastric Cancer guidelines on June 13th, 2025 (Version 1.2025). Included in these new guidelines are updates to the CDH1 content as outlined below: HGAST-A (Page 97) HGAST-A (Page 97) To read more, check out the full guidelines by creating a FREE account …
Permanent link to this article: https://inheritedcancer.net/post081125/
ICARE Social Media Post August 2025
NCCN BOPP Guidelines (V1.2026): CHEK2
ICARE Social Media Post August 2025
NCCN BOPP Guidelines (V1.2026): CHEK2
The National Comprehensive Cancer Network (NCCN) recently released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate Cancer guidelines (Version 1.2026), which included updates to CHEK2 content. To learn more, check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bopp.pdf
Permanent link to this article: https://inheritedcancer.net/post080825/
Click below to read recent updates on inherited cancers
Click below to read inspiring stories from our ICARE participants
